Skip to content
Buy This GLP

$69 lowest all-in per month, across 432 sellers

← Research
Evidence

The surgery nobody puts in the price

Aesthetic procedures among people who used a GLP-1 grew 53.8% a year after 2021. That is growth inside the surgical population, not a risk figure for anybody taking the drug.

Carla Medina5 min read
Mean annual growth in aesthetic proceduresGLP-1 users53.8%post-bariatric-4%Among people having aesthetic surgery — not a share of everyone taking the drug

Lose fifty pounds quickly and the skin does not always follow. Some people mind and some do not. The ones who mind and can afford to act on it end up in a surgeon’s office, and that visit is not in anybody’s price comparison — not even in the careful version of the arithmetic.

What was counted, and what was not

Researchers took a large health-records database, identified people who had aesthetic procedures between 2016 and 2024, and split them by whether they had previously had bariatric surgery or used a GLP-1. [1] Between 2016 and 2021, the mean annual growth rate of procedures among GLP-1 users was 36.1% a year against 27.1% among post-bariatric patients, P=.0026. After 2021, GLP-1 users rose to 53.8% a year, +17.7% with a 95% CI of 10.4% to 25.4%, while the post-bariatric group fell to −4%, a change of −31.1% with a 95% CI of −37.7% to −25.5%.

The complication finding favors the drug

After propensity matching, the post-bariatric patients had the worse surgical course. Hematoma came in at RR 1.99, 95% CI 1.10 to 3.62. Infection at RR 1.37, 95% CI 1.01 to 1.88. Emergency department use at RR 1.54, 95% CI 1.05 to 2.26. All at P < .05.

That is a real point in favor of the drug route and it should be read with the usual discount. These are two very different populations — one had major abdominal surgery and a different weight trajectory — and matching on recorded variables does not make them comparable. The authors call for work on the underlying factors, which is the right request.

Why this belongs on a price page

Because body contouring is cash. Insurance covers it rarely and narrowly, usually only where skin causes documented medical problems. A cosmetic procedure after weight loss is paid the way the drug is paid: out of pocket, by the person who bought the drug.

That does not make it a hidden cost of the prescription, and it would be dishonest to frame it as one. Most people will not have surgery. But the monthly figure on a product page is presented as the cost of the outcome, and it is not — it is the cost of the drug. The other things a year of rapid weight loss can lead to belong in the same ledger as everything else nobody itemizes.

What to take from it

Not a reason to avoid the drug, and not a reason to plan surgery. Two narrower things. First, loose skin is a known consequence of fast weight loss and no seller on this roster mentions it, in the same way nobody mentions what happens when you stop. Second, if it matters to you, slower loss and attention to lean mass are the levers that exist, and both are decisions made at the start rather than at the end.

Price the drug against what you want from it, not against the best case. The six-month view is the honest starting point, and it is still only the drug.

Frequently asked

What share of GLP-1 users end up having surgery?
This study cannot say. It counted people already having aesthetic procedures and measured how the mix changed, so its denominator is surgical patients rather than drug users.
Is surgery riskier after the drug than after bariatric surgery?
The opposite, in this data. Matched post-bariatric patients had higher rates of hematoma, infection and emergency department use than GLP-1 users.
Will insurance pay for it?
Usually not. Body contouring is generally covered only where excess skin causes documented medical problems, so most of it is paid out of pocket.
Can loose skin be avoided?
Not reliably. Slower weight loss and attention to preserving lean mass are the levers people actually have, and both are choices made at the start rather than afterward.

Sources

  1. [1] Khong C, et al. (2025). New Contours, Different Risks: A 9-Year Comparison of Trends and Postoperative Complications in Patients Undergoing Aesthetic Surgery With Previous Bariatric Surgery Vs Glucagon-Like Peptide 1 Receptor Agonist Use Aesthetic Surgery Journal. PMID 40692274

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk

More in Evidence